



Press release

LINK Healthcare PTE LTD and photonamic GmbH & Co. KG sign a licensing agreement for Alacare[®], a new therapeutic for the treatment of actinic keratosis.

- This licensing agreement gives LINK exclusive rights to market Alacare[®] in Australia, New Zealand and South Africa.
- Alacare[®] is a photodynamic therapeutic in the form of a medicated patch for the treatment of actinic keratosis.

Wedel/Singapore/Sydney/Pretoria/Tokyo/Auckland: 24st June 2013.

Specialist regional (Asian/Australasian/African) pharmaceutical company LINK Healthcare PTE LTD ('LINK') and the research company photonamic GmbH & Co. KG, ('Photonamic') of Wedel, Germany, have signed an exclusive licensing agreement for the registration and marketing of Alacare[®]. The Alacare[®] patch system was developed by Photonamic for the treatment of actinic keratosis, a precursor stage of non-melanoma skin cancer. It is already approved for marketing in 12 EU countries and is protected worldwide by patents until 2022.

Alacare[®] medicated patches contain the active ingredient 5-aminolevulinic acid and are intended for the treatment of mild actinic keratosis (AK) on the face and scalp in combination with brief exposure to red light – photodynamic therapy (PDT). The most common form of treatment for AK currently involves the use of liquid nitrogen to "freeze" the lesion causing some skin redness and crusting until the area is replaced by new skin.

CEO of photonamic GmbH, Dr Ulrich Kosciessa, said Alacare[®] has aroused great interest amongst the experts to whom it has been presented.

"In comparison with the methods used previously, Alacare[®] is particularly interesting, as it is very easy and convenient for the doctor to use. In addition, the very good clinical results are combined with excellent cosmetic outcomes, something that is especially important on the face" explained Dr Kosciessa.

Actinic keratoses are very common in fair-skinned people in countries like South Africa and New Zealand, and most prevalent in Australia where approximately 50% of the population over the age of 40 years is affected. Long-term sun exposure is a major risk factor.

Executive Chairman of LINK Healthcare, John Bacon, commented:

“The acquisition of Alacare® is extremely exciting for our group because it is a new therapeutic concept for an extremely common problem, particularly in our region. With Alacare® we can expand on our plans to penetrate the highly specialised segment of dermatology therapies” he said.

Contact persons:

Mr John Bacon, Executive Chairman
LINK Healthcare
+61 2 8401 9777

Dr Ulrich Kosciessa, CEO
photonamic GmbH & Co. KG
+49 4103 8006 701

About LINK Healthcare (Singapore/Australia, New Zealand, Southern Africa & Japan)

LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK’s mission is to strive for excellence in the marketing of vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa. LINK provides exceptional regulatory, sales, marketing, customer service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of ‘medicine that matters.’

For more information about LINK Healthcare visit www.linkhealthcare.com.au

About photonamic GmbH & Co KG

photonamic GmbH & Co. KG, with its headquarters in Wedel, Germany, is a research company active in the fields of photodynamic therapy (PDT) and fluorescence diagnostics (FD). As a small, young company, Photonamic has already developed two products ready for the market in only eight years.

Alacare® makes use of the therapeutic potential of aminolevulinic acid combined with light exposure in the topical treatment of conditions such as mild actinic keratosis.

Photonamic is currently developing other photosensitisers for use in PDT and FD.